Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy

a systematic guideline review and expert consensus

C. Muth, J. W. Blom, S. M. Smith, K. Johnell, A. I. Gonzalez-Gonzalez, T. S. Nguyen, M. S. Brueckle, M. Cesari, M. E. Tinetti, J. M. Valderas

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The complexity and heterogeneity of patients with multimorbidity and polypharmacy renders traditional disease-oriented guidelines often inadequate and complicates clinical decision making. To address this challenge, guidelines have been developed on multimorbidity or polypharmacy. To systematically analyse their recommendations, we conducted a systematic guideline review using the Ariadne principles for managing multimorbidity as analytical framework. The information synthesis included a multistep consensus process involving 18 multidisciplinary experts from seven countries. We included eight guidelines (four each on multimorbidity and polypharmacy) and extracted about 250 recommendations. The guideline addressed (i) the identification of the target population (risk factors); (ii) the assessment of interacting conditions and treatments: medical history, clinical and psychosocial assessment including physiological status and frailty, reviews of medication and encounters with healthcare providers highlighting informational continuity; (iii) the need to incorporate patient preferences and goal setting: eliciting preferences and expectations, the process of shared decision making in relation to treatment options and the level of involvement of patients and carers; (iv) individualized management: guiding principles on optimization of treatment benefits over possible harms, treatment communication and the information content of medication/care plans; (v) monitoring and follow-up: strategies in care planning, self-management and medication-related aspects, communication with patients including safety instructions and adherence, coordination of care regarding referral and discharge management, medication appropriateness and safety concerns. The spectrum of clinical and self-management issues varied from guiding principles to specific recommendations and tools providing actionable support. The limited availability of reliable risk prediction models, feasible interventions of proven effectiveness and decision aids, and limited consensus on appropriate outcomes of care highlight major research deficits. An integrated approach to both multimorbidity and polypharmacy should be considered in future guidelines.

Original languageEnglish
Pages (from-to)272-288
JournalJournal of Internal Medicine
Volume285
Issue number3
DOIs
Publication statusPublished - 2019

Fingerprint

Polypharmacy
Comorbidity
Consensus
Guidelines
Self Care
Communication
Self Medication
Decision Support Techniques
Patient Preference
Health Services Needs and Demand
Therapeutics
Patient Safety
Health Personnel
Caregivers
Decision Making
Referral and Consultation
Safety
Research

Keywords

  • continuity of patient care
  • multimorbidity
  • older adults
  • patient-centred care
  • polypharmacy
  • practice guideline

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy : a systematic guideline review and expert consensus. / Muth, C.; Blom, J. W.; Smith, S. M.; Johnell, K.; Gonzalez-Gonzalez, A. I.; Nguyen, T. S.; Brueckle, M. S.; Cesari, M.; Tinetti, M. E.; Valderas, J. M.

In: Journal of Internal Medicine, Vol. 285, No. 3, 2019, p. 272-288.

Research output: Contribution to journalArticle

Muth, C, Blom, JW, Smith, SM, Johnell, K, Gonzalez-Gonzalez, AI, Nguyen, TS, Brueckle, MS, Cesari, M, Tinetti, ME & Valderas, JM 2019, 'Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus', Journal of Internal Medicine, vol. 285, no. 3, pp. 272-288. https://doi.org/10.1111/joim.12842
Muth, C. ; Blom, J. W. ; Smith, S. M. ; Johnell, K. ; Gonzalez-Gonzalez, A. I. ; Nguyen, T. S. ; Brueckle, M. S. ; Cesari, M. ; Tinetti, M. E. ; Valderas, J. M. / Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy : a systematic guideline review and expert consensus. In: Journal of Internal Medicine. 2019 ; Vol. 285, No. 3. pp. 272-288.
@article{ea801db8c3dd40c99cf1f61eeb19bbc5,
title = "Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus",
abstract = "The complexity and heterogeneity of patients with multimorbidity and polypharmacy renders traditional disease-oriented guidelines often inadequate and complicates clinical decision making. To address this challenge, guidelines have been developed on multimorbidity or polypharmacy. To systematically analyse their recommendations, we conducted a systematic guideline review using the Ariadne principles for managing multimorbidity as analytical framework. The information synthesis included a multistep consensus process involving 18 multidisciplinary experts from seven countries. We included eight guidelines (four each on multimorbidity and polypharmacy) and extracted about 250 recommendations. The guideline addressed (i) the identification of the target population (risk factors); (ii) the assessment of interacting conditions and treatments: medical history, clinical and psychosocial assessment including physiological status and frailty, reviews of medication and encounters with healthcare providers highlighting informational continuity; (iii) the need to incorporate patient preferences and goal setting: eliciting preferences and expectations, the process of shared decision making in relation to treatment options and the level of involvement of patients and carers; (iv) individualized management: guiding principles on optimization of treatment benefits over possible harms, treatment communication and the information content of medication/care plans; (v) monitoring and follow-up: strategies in care planning, self-management and medication-related aspects, communication with patients including safety instructions and adherence, coordination of care regarding referral and discharge management, medication appropriateness and safety concerns. The spectrum of clinical and self-management issues varied from guiding principles to specific recommendations and tools providing actionable support. The limited availability of reliable risk prediction models, feasible interventions of proven effectiveness and decision aids, and limited consensus on appropriate outcomes of care highlight major research deficits. An integrated approach to both multimorbidity and polypharmacy should be considered in future guidelines.",
keywords = "continuity of patient care, multimorbidity, older adults, patient-centred care, polypharmacy, practice guideline",
author = "C. Muth and Blom, {J. W.} and Smith, {S. M.} and K. Johnell and Gonzalez-Gonzalez, {A. I.} and Nguyen, {T. S.} and Brueckle, {M. S.} and M. Cesari and Tinetti, {M. E.} and Valderas, {J. M.}",
year = "2019",
doi = "10.1111/joim.12842",
language = "English",
volume = "285",
pages = "272--288",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy

T2 - a systematic guideline review and expert consensus

AU - Muth, C.

AU - Blom, J. W.

AU - Smith, S. M.

AU - Johnell, K.

AU - Gonzalez-Gonzalez, A. I.

AU - Nguyen, T. S.

AU - Brueckle, M. S.

AU - Cesari, M.

AU - Tinetti, M. E.

AU - Valderas, J. M.

PY - 2019

Y1 - 2019

N2 - The complexity and heterogeneity of patients with multimorbidity and polypharmacy renders traditional disease-oriented guidelines often inadequate and complicates clinical decision making. To address this challenge, guidelines have been developed on multimorbidity or polypharmacy. To systematically analyse their recommendations, we conducted a systematic guideline review using the Ariadne principles for managing multimorbidity as analytical framework. The information synthesis included a multistep consensus process involving 18 multidisciplinary experts from seven countries. We included eight guidelines (four each on multimorbidity and polypharmacy) and extracted about 250 recommendations. The guideline addressed (i) the identification of the target population (risk factors); (ii) the assessment of interacting conditions and treatments: medical history, clinical and psychosocial assessment including physiological status and frailty, reviews of medication and encounters with healthcare providers highlighting informational continuity; (iii) the need to incorporate patient preferences and goal setting: eliciting preferences and expectations, the process of shared decision making in relation to treatment options and the level of involvement of patients and carers; (iv) individualized management: guiding principles on optimization of treatment benefits over possible harms, treatment communication and the information content of medication/care plans; (v) monitoring and follow-up: strategies in care planning, self-management and medication-related aspects, communication with patients including safety instructions and adherence, coordination of care regarding referral and discharge management, medication appropriateness and safety concerns. The spectrum of clinical and self-management issues varied from guiding principles to specific recommendations and tools providing actionable support. The limited availability of reliable risk prediction models, feasible interventions of proven effectiveness and decision aids, and limited consensus on appropriate outcomes of care highlight major research deficits. An integrated approach to both multimorbidity and polypharmacy should be considered in future guidelines.

AB - The complexity and heterogeneity of patients with multimorbidity and polypharmacy renders traditional disease-oriented guidelines often inadequate and complicates clinical decision making. To address this challenge, guidelines have been developed on multimorbidity or polypharmacy. To systematically analyse their recommendations, we conducted a systematic guideline review using the Ariadne principles for managing multimorbidity as analytical framework. The information synthesis included a multistep consensus process involving 18 multidisciplinary experts from seven countries. We included eight guidelines (four each on multimorbidity and polypharmacy) and extracted about 250 recommendations. The guideline addressed (i) the identification of the target population (risk factors); (ii) the assessment of interacting conditions and treatments: medical history, clinical and psychosocial assessment including physiological status and frailty, reviews of medication and encounters with healthcare providers highlighting informational continuity; (iii) the need to incorporate patient preferences and goal setting: eliciting preferences and expectations, the process of shared decision making in relation to treatment options and the level of involvement of patients and carers; (iv) individualized management: guiding principles on optimization of treatment benefits over possible harms, treatment communication and the information content of medication/care plans; (v) monitoring and follow-up: strategies in care planning, self-management and medication-related aspects, communication with patients including safety instructions and adherence, coordination of care regarding referral and discharge management, medication appropriateness and safety concerns. The spectrum of clinical and self-management issues varied from guiding principles to specific recommendations and tools providing actionable support. The limited availability of reliable risk prediction models, feasible interventions of proven effectiveness and decision aids, and limited consensus on appropriate outcomes of care highlight major research deficits. An integrated approach to both multimorbidity and polypharmacy should be considered in future guidelines.

KW - continuity of patient care

KW - multimorbidity

KW - older adults

KW - patient-centred care

KW - polypharmacy

KW - practice guideline

UR - http://www.scopus.com/inward/record.url?scp=85058291080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058291080&partnerID=8YFLogxK

U2 - 10.1111/joim.12842

DO - 10.1111/joim.12842

M3 - Article

VL - 285

SP - 272

EP - 288

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 3

ER -